Interim report
Q2 2024

alzinova

We will make it possible for Alzheimer's patients to live an *independent and active life.*

Highlights

Oversubscribed rights issue

Alzinova carried out an oversubscribed rights issue during the second quarter, which was subscribed to approximately 106%.

Continued progress with ALZ-101

All patients have been enrolled and dosed in the final cohort (high-dose) of the phase 1b study (A2).

Strong data presented at AAIC

The promising results from part A1 of the phase 1b study were presented at the Alzheimer's Association International Conference, AAIC.

Key figures from the period

THREE MONTHS, APRIL–JUNE, 2024

- Net sales amounted to SEK 30 thousand (0).
- Loss after financial items amounted to SEK -4,963 thousand (-4,272).
- Average number of shares during the period before dilution amounted to 44,531,265 (32,419,034).
- Average number of shares during the period after dilution amounted to 44,531,265 (45,545,811).
- Earnings per share before dilution amounted to SEK -0.11 (-0.13).
- Earnings per share after dilution amounted to SEK -0.11 (-0.09).

SIX MONTHS, JANUARY–JUNE, 2024

- Net sales amounted to SEK 30 thousand (0).
- Loss after financial items amounted to SEK -4,963 thousand (-4,272).
- Average number of shares during the period before dilution amounted to 44,531,265 (32,419,034).
- Average number of shares during the period after dilution amounted to 44,531,265 (45,545,811).
- Earnings per share before dilution amounted to SEK -0.11 (-0.13).
- Earnings per share after dilution amounted to SEK -0.11 (-0.09).

Amounts in brackets: Corresponding period in previous year.
"the Company" or "Alzinova" refers to Alzinova AB with corporate identity number: 556861-8168.

Significant events during the second quarter 2024

- All patients in the extension part (part B) of the phase 1b study were dosed with the last dose of the Alzheimer's disease vaccine candidate ALZ-101 in April.
- An in-depth analysis of data from part A1 of Alzinova's phase 1b study with the vaccine candidate ALZ-101 was conducted in April. The analysis indicated that patients with the higher antibody levels after vaccination have a positive effect on biomarkers associated with Alzheimer's disease.
- Alzinova's CEO, Kristina Torfgård, informed the Board of Directors at the end of April of her wish to step down as CEO of the company.
- Alzinova's Board of Directors decided, with the support of authorisation from the Annual General Meeting 2023, on a rights issue of shares of approximately SEK 34.4 million.
- In May, the first patient was dosed in the final cohort (part A2) of the phase Ib study. Part A2 aims to evaluate a higher dose of ALZ-101.
- The minutes of the Annual General Meeting were published. All proposals for resolutions were adopted by the meeting. Lena Degling Wikingsson left the Board of Directors in connection with the AGM and the Board subsequently consists of Julian Aleksov (Chairman), Anders Blom, Per-Göran Gillberg, Clas Malmeström, Carol Routledge and Anders Waas.
- Alzinova announced that a new external safety review of part A2 of the Company's phase 1b clinical trial has been completed - with a positive assessment to continue the study as planned.
- Enrolment of patients in Alzinova's part A2 of the phase 1b study was completed at the end of June.
- Alzinova announced a change of Certified Adviser and Liquidity Provider. The changes came into effect on 1 July 2024.
- Alzinova's rights issue was oversubscribed with a subscription rate of approximately 106%. The company raised approximately SEK 34.4 million before deduction of issue costs. No underwriting commitments were utilized.

Significant events after the end of the second quarter 2024

- All patients in part A2 of the phase 1b study had received the first dose of ALZ-101 by July.
- The Board of Directors decided to appoint Board member Carol Routledge as acting CEO of Alzinova from August 1, 2024, until a permanent CEO is recruited.
- Alzinova published further details of the data presented in a poster presentation at AAIC in July 2024.
- Alzinova updated the market that the Company has accelerated the partnering process. Among other things the Company has engaged with a renowned US Adviser, covering life sciences consulting, M&A and investment banking, to assist the company in identifying and subsequently signing a partner agreement.
- In August, the Company updated the market on the status of the various parts of Alzinova's phase 1b study.

A word from acting CEO Carol Routledge

”We have now completed six months that have strengthened Alzinova’s position as a leading actor in the research and development of treatments for Alzheimer’s disease.”

It has been an exceptional six months for Alzinova, filled with progress and events that strengthened our journey towards fighting Alzheimer’s disease. On June 17, the subscription period for our rights issue ended, resulting in a subscription rate of 106.2%. We raised approximately SEK 30.8 million after issue costs, providing us with the necessary resources to continue our clinical development without taking on any underwriter commitments. The support from our shareholders, in the current market climate, is a strong testament to the confidence in our strategy and our ability to deliver.

Alzinova presented promising phase 1b results

Several steps forward have also been taken in the ongoing phase 1b study. We have dosed all patients with the last dose of the vaccine candidate ALZ-101 in the extension cohort (part B). An in-depth analysis of the data from part A1 of the same study, conducted in April 2024, showed that patients with higher antibody levels following vaccination with ALZ-101, exhibited positive effects on biomarkers associated with Alzheimer’s disease. The results again highlight the potential of ALZ-101 and strengthen our position in partner dialogues.

In June, we presented the phase 1b results of ALZ-101 to senior executives from several Big Pharma companies at the Biotech International Convention, US Bio. Additionally, Henrik Zetterberg, Professor of Neurochemistry at University College London, UK and at Gothenburg University as well as Scientific Advisor to Alzinova, presented an abstract with the strong results from part A1 of the phase 1b study with ALZ-101 at the major Alzheimer’s conference AAIC in July.

The goal is to establish global partnerships through which our vaccine candidate is further developed to reach the market as quickly as possible. The timing is optimal after AC Immune’s lucrative out-licensing of the vaccine ACI-24, which like ALZ-101, targets amyloid beta. The critical and important difference between Alzinova’s treatment and AC Immune’s approach is that the vaccine candidate ALZ-101 is significantly more specific in targeting toxic oligomers vs other forms of amyloid beta. The specificity, together with the phase 1b results for ALZ-101, means that Alzinova offers an attractive treatment approach with their drug candidate. Alzinova is right on track with a potentially more efficient and safer product. With its novel treatment approach, ALZ-101 has the potential to be best in class, and I am convinced that we are and will be an valuable addition for Big Pharma’s Alzheimer’s portfolio. The demand for therapies that are easy and cost-effective for healthcare professionals to administer is high, which is also reflected in the potentially high sales value of such products.

Progress in the phase 1b study and positive safety review

On the clinical development front, we have made further progress. In May, the first patient was dosed in the last cohort (part A2) of the phase 1b study, and according to schedule, enrolment of all patients in part A2 was also completed. A new external safety review of our phase 1b study resulted in a positive assessment, allowing us to continue the study as planned. Shortly after the end of the quarter, we were also able to announce that all patients had received the first dose of ALZ-101 in part A2 of the phase 1b study. The treatment is administered a total of four times to each patient over a 16-week period, followed by a further four weeks of monitoring. Our goal is to present data from the high-dose cohort in the fourth quarter of 2024.

Strengthened position for Alzinova

At a corporate level, there have been important changes. CEO, Kristina Torfgård, announced her decision to step down before the summer. We thank Kristina for her invaluable contribution and wish her all the best in her future endeavors. I am grateful for the Board’s confidence in me to lead Alzinova as acting CEO until the Board has finalised the recruitment of a permanent CEO.

We have now completed six months that have strengthened Alzinova’s position as a leading actor in the research and development of treatments for Alzheimer’s disease. With the funds Alzinova has received from the successful share issue and the positive clinical results, the company is well equipped for the future and has a strengthened position in partnership dialogues.

Thank you to the Alzinova team for all the hard work and dedication, to all patients and their families for their trust, and to you, our shareholders, for your continued support. Together, we are taking important steps forward in the fight against Alzheimer’s disease.

Carol Routledge,
acting CEO of Alzinova AB

Investment highlights

Vaccine with potential to treat Alzheimer's

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine to treat Alzheimer's disease. Positive results from part A1 of the ongoing study demonstrate good safety and tolerability and a clear immunological response.

Supplementary treatment with antibody

Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to the vaccine to combat Alzheimer's disease.

Best-in-class potential with favourable safety profile

Data show that the unique specificity of Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) provides "best-in-class" potential with a more favourable side effect profile compared to other treatments.

Regulatory progress boost collaborations

Positive feedback from the FDA and EMA as well as other ongoing activities for the next clinical development phase, together with strong IP, make Alzinova's candidates attractive for strategic partnerships.

Enables an independent and active life

About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's patented AβCC peptide technology™ enables the development of disease-modifying therapies with the potential to selectively neutralize the toxic accumulations of the amyloid beta peptide, so-called oligomers, which are central to the onset and progression of Alzheimer's disease.

With this technology, we can develop effective treatments that have a favorable profile with a lower risk of side effects compared to other treatments. Promising preclinical results have been obtained following a study on brain extracts from deceased Alzheimer's patients, demonstrating evidence of the mechanism of these actions.

Alzinova's primary focus is the development of a vaccine that is being developed as a long-acting treatment for Alzheimer's disease. The vaccine candidate ALZ-101 is in clinical development with a phase 1b study in Alzheimer's patients started Q3 2021. Based on positive interim data from part A1, the Company has initiated an extension part, part B, of the study, which is expected to be completed in early 2025.

Part A1 of the study was completed at the end of 2023 with positive results, showing ALZ-101 to be both safe and well tolerated. In addition, a clear immunological response was noted as well as a response in biomarkers associated with Alzheimer's disease. The results from the complete analysis of part A1 open up the possibility of evaluating a further, higher dose. Alzinova has therefore initiated dosing an additional cohort with 400 µg of ALZ-101, which was implemented in 2024. Overall, the results of preclinical and clinical studies mean that Alzinova has the potential to develop a treatment that is differentiated from other treatments currently on the market.

Based on the same AβCC peptide technology, the Company is also developing the ALZ-201 antibody, which is currently in preclinical development. The project portfolio for the development of disease-modifying treatments is being broadened as the Company prepares the antibody for clinical development. Alzinova was founded by researchers who have worked at the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

2007 **Research project** University of Gothenburg

2009 **Company is formed** Gothenburg

2011 **Vaccine ALZ-101** Research phase

2015 **Vaccine ALZ-101** Preclinical phase

2020 **Antibody ALZ-201** Preclinical phase

2021 **Vaccine ALZ-101** Clinical phase 1b-study

2022 **Vaccine ALZ-101** Increased production

2023 **Vaccine ALZ-101** Clinical phase 1b results

+2024 **Vaccine ALZ-101** Start phase 2 study

Alzheimer's disease

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually, due to synaptic impairment, the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous monitoring.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over the age of 65, and in these cases there is not a strong genetic component driving the disease.

Alzheimer's is most common in the elderly population, with 1 in 9 people over 65 affected, 65% of whom are women. However, about 5% of cases are diagnosed at an earlier age.



Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated as well as demonstrating proof-of-concept, i.e. that they exhibit efficacy in patients with Alzheimer's disease. Based on positive clinical data, the Company has identified several potential strategic partners who have the resources and in-house expertise to conduct the studies needed for registration and commercialisation. This can be done through out-licensing with a partnership where the Company jointly brings the drug to the market with the collaboration partner, or or by selling the drug candidate for further development.

Out-licensing

A common alternative for development companies like Alzinova is to out-license projects to one or more pharmaceutical companies. Either these can get exclusivity in a limited market, and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future installments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. With positive results in the Company's two drug projects, ALZ-101 and ALZ-201, there are several options. One is to out-license the ALZ-101 vaccine to a major pharmaceutical company, and another option is for Alzinova to take ALZ-101 through phase 2 and then out-license it to a partner. For the antibody ALZ-201, this could be out-licensed immediately during the preclinical phase, or alternatively after phase 1b studies. The Company's focus going forward is on business development with several ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year around 10 million people in the world become ill with some form of dementia, of which Alzheimer's disease accounts for around 60-70 %. Today, it is estimated that there are approximately 55 million patients with dementia in the world, but it is difficult to diagnose dementia today at early stages of disease. Therefore, it is expected that this figure is significantly higher. In addition, this number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050[1].

The societal costs of dementia diseases are currently estimated at $1,300 billion annually[2]. The drug cost of Alzheimer's medications, which are symptom relief alone, amounts to approximately $6 billion annually. While the first disease-modifying drugs has recently been approved in the United States, Japan and China there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective disease-modifying drug is therefore significant even if it would only have an initially limited market share. By 2026, drugs for Alzheimer's disease are expected to be represented among 2 out of 7 expected top sellers (pharmaceutical companies), with an expected annual turnover of USD 1.7-4.5 billion[3]. The reason why the initial sales estimates are relatively low is that there have been no good medical alternatives. With effective treatment options coming to the market, such as Alzinova's drug, the Company estimates that annual sales can be multiplied several times compared to today.

The research firm Global Data estimates that annual sales for disease-modifying drugs for Alzheimer's disease will reach roughly $13 billion by 2028 in the largest markets: the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, China, and India. An approved disease-modifying treatment for Alzheimer's disease has the potential to generate peak annual sales in excess of USD 10 billion[4].

1) World Health Organization (WHO) – Facts about Dementia, March 2023
2) World Alzheimer's Report, 2021.
3) Drugs to watch report, 2022.
4) US, Germany, France, UK, Italy, Spain, Japan, China. GlobalData, Pharma, June 7, 2023.

Alzinova's competitive advantages



Based on statistics from Statistics Sweden (SCB) about the Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost.

Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatments such as antibodies, is expected to require only a few doses a year rather than as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

To treat patients with therapeutic antibodies, this sharply increases societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive treatment.

Financial information

Corporate structure and shareholding
Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development
During the period April - June 2024, the Company has continued to invest in the further development of ALZ-101, which is in the final phase of the phase 1b study, where an open extension part and a high dose part have been initiated. The Company is also investing in preparations for clinical phase 2. The Company has also started preparations for clinical studies of the antibody ALZ-201, with the goal of treating and also preventing the progression of Alzheimer's disease.

The Company's total costs during the second quarter of 2024 amounted to SEK 7,652 (9,926) thousand. Of the period's costs, SEK 2,885 (6,018) thousand relate to research and development costs (R&D), including costs for the ongoing clinical study (including the extension part), as well as preparation for the production of drug substance before the start of the upcoming phase 2 clinical study. The company's R&D costs have been capitalized in the balance sheet. Of the total costs, personnel costs during the period amounted to SEK 2,314 (2,036) thousand.

The cash flow from operating activities during the second quarter of the year amounted to SEK -5,135 (-4,894) thousand. The cash flow from investment activities consists of expenses for ongoing capitalized R&D costs during Q2 and amounted to SEK -2,885 (-6,018) thousand. The cash flow from financing activities during the period amounted to SEK 0 (24,805) thousand.

Financial position
At the end of the period, the Company's equity amounted to approximately SEK 104,820 (122,138) thousand with an equity ratio of 92.5 % (96.4%), and total cash balances amounted to approximately SEK 4,987 (36,580) thousand.

Rights issue
After the end of the quarter, the Company completed an oversubscribed rights issue, which in total provided the Company with SEK 34.4 million before issue costs of approximately SEK 3.6 million. After registration, the number of shares in Alzinova has increased by 44,634,195 shares, to a total of 89,165,460 shares, with a total share capital of SEK 23,450,516. For shareholders who did not participate in the rights issue, the dilution amounted to approximately 50% based on the total number of shares in the Company.

Risk factors
A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2023 and in the prospectus published in connection with the rights issue in June 2024.

Auditor's review
This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report
The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, August 22, 2024
Alzinova AB (publ)

Income statement

(TSEK)	2024-04-01 2024-06-30 3 months	2023-04-01 2023-06-30 3 months	2024-01-01 2024-06-30 6 months	2023-01-01 2023-06-30 6 months	2023-01-01 2023-12-31 12 months
Net sales	-	-	30	-	270
Own work capitalized	2,885	6,018	5,708	10,690	19,604
	2,885	6,018	5,738	10,690	19,874
Operating expenses					
Other external expenses	-5,338	-7,890	-10,569	-14,881	-27,097
Personnel expenses	-2,314	-2,036	-4,900	-3,990	-9,299
Operating result	**-4,767**	**-3,908**	**-9,731**	**-8,180**	**-16,522**
Result from financial items					
Interest income	0	0	1	1	140
Interest expenses	-109	-21	-107	-21	-98
Result after financial items	**-4,876**	**-3,928**	**-9,838**	**-8,200**	**-16,480**
Result before tax	**-4,876**	**-3,928**	**-9,838**	**-8,200**	**-16,480**
Result for the period	**-4,876**	**-3,928**	**-9,838**	**-8,200**	**-16,480**

Balance sheet

(TSEK)	30 June 2024	30 June 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	101,961	87,339	96,253
Patent	1,632	1,632	1,632
	103,593	**88,971**	**97,885**
Total fixed assets	**103,593**	**88,971**	**97,885**
Current assets			
Short term receivables			
Tax receivables	197	190	257
Other receivables	259	617	378
Prepaid expenses and accrued income	3,362	380	2,643
	3,819	**1,187**	**3,278**
Cash and cash receivables	**4,987**	**36,580**	**22,026**
Total current assets	**8,805**	**37,767**	**25,304**
TOTAL ASSETS	**112,399**	**126,738**	**123,189**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	11,712	11,712	11,712
Fund for development costs	99,897	85,276	94,190
	111,609	**96,988**	**105,902**
Unrestricted equity			
Share premium	166,264	166,264	166,264
Retained result	-164,015	-132,914	-141,828
Result for the year/period	-9,838	-8,200	-16,480
	-7,589	**25,150**	**7,956**
Total equity	**104,020**	**122,138**	**113,858**
Long term liabilities			
Other long term liabilities	800	800	800
	800	**800**	**800**
Current liabilities			
Accounts payable	2,248	1,925	2,493
Other current liabilities	3,286	203	3,413
Accrued expenses and prepaid income	2,045	1,672	2,625
	7,579	**3,800**	**8,531**
TOTAL EQUITY AND LIABILITIES	**112,399**	**126,738**	**123,189**

Change in equity, condensed

(TSEK)

Jan-June 2024 6 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**
Transfer within equity	0	5,707	0	-5,707	0
Net result for the period	0	0	0	-9,838	-9,838
At the end of the period	**11,712**	**99,897**	**166,264**	**-173,853**	**104,020**

(TSEK)

Jan - June 2023 6 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,223**	**105,533**
Share issue	3,186	0	23,098	0	26,284
Transaction costs share issue	0	0	-1,479	0	-1,479
Transfer within equity	0	10,690	0	-10,690	0
Net result for the period	0	0	0	-8,200	-8,200
At the end of the period	**11,712**	**85,276**	**166,264**	**-141,114**	**122,138**

(TSEK)

Jan - Dec 2023 12 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Share issue	3,186	0	23,098	0	26,284
Transaction costs share issue	0	0	-1,479	0	-1,479
Transfer within equity	0	19,604	0	-19,604	0
Net result for the period	0	0	0	-16,480	-16,480
At the end of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**

Cash flow statement, condensed

(TSEK)	2024-04-01 2024-06-30 3 months	2023-04-01 2023-06-30 3 months	2024-01-01 2024-06-30 6 months	2023-01-01 2023-06-30 6 months	2023-01-01 2023-12-31 12 months
OPERATING ACTIVITIES					
Result after financial items	-4,876	-3,928	-9,838	-8,200	-16,480
Cash flow from operating activities before change in working capital	**-4,876**	**-3,928**	**-9,838**	**-8,200**	**-16,480**
Cash flow from change in working capital					
Increase (-)/Decrease (+) in operating receivables	-466	239	-541	116	-1,976
Increase (+)/Decrease (-) in operating liabilities	207	-1,205	-952	-1,489	3,243
Cash flow from operating activities	**-5,135**	**-4,894**	**-11,331**	**-9,573**	**-15,213**
Investing activities					
Acquisition of intangible fixed assets	-2,885	-6,018	-5,708	-10,690	-19,604
Cash flow from investing activities	**-2,885**	**-6,018**	**-5,708**	**-10,690**	**-19,604**
Financing activities					
Share issue	0	26,284	0	26,284	26,284
Transaction costs share issue	0	-1,479	0	-1,479	-1,479
Cash flow from financing activities	**0**	**24,805**	**0**	**24,805**	**24,805**
Cash flow for the period	**-8,020**	**13,893**	**-17,039**	**4,542**	**-10,012**
Cash and cash equivalents at the beginning of the period	**13,007**	**22,687**	**22,026**	**32,038**	**32,038**
Cash and cash equivalents at the end of the period	**4,987**	**36,580**	**4,987**	**36,580**	**22,026**

The share

Alzinova's share was listed on the Spotlight Stock Market (formerly Aktietorget) on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of June 30, 2024, the number of shares in Alzinova amounted to 44 531 265 (44 531 265 as of June 30, 2023). The shares newly issued in the rights issue in June 2024 are not included in the table below.

Largest owners per June 28, 2024

Owner	*Number of shares*	*Capital %*
Maida Vale Capital AB	6,748,920	15.16%
Försäkrings AB Avanza pension	3,038,512	6.82%
Nordnet Pensionsförsäkring AB	1,358,232	3.05%
Patrik Ahlvin	1,004,750	2.26%
Sara Gjertz	753,015	1.69%
MIVAC Development AB	711,787	1.60%
Özlem Erdogdu Gül	718,063	1.61%
MGC Capital Ltd	604,171	1.36%
Moll Invest AB	600,080	1.35%
Bertil Nilsson	525,000	1.18%
Total 10 largest shareholders	**16,062,530**	**36.08%**
Total other shareholders	28,468,735	63.92%
Total all shareholders	**44,531,265**	**100.00%**

Stock exchange	Ticker	Listed since
Nasdaq First North Growth Market	*ALZ*	*2015*

Currently there are no long-term share-based incentive programs in the Company.

Financial calendar

Interim report 3, 2024	14 November 2024
Year-end report, 2024	27 February 2024

Financial reports are available on the Company's website www.alzinova.com as of the date of publication.

Contact

Carol Routledge, acting CEO,
carol.routledge@alzinova.com, +44 790 900 24 18

Erik Kullgren, interim CFO,
erik.kullgren@alzinova.com, +46 707 439 516

or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
"Best-in-class"	A product that is considered superior to other competitors in its class, can be compared to 'first-in-class', which refers to being first to market with a product
Biomarker	A measurable indicator of a state of disease
Clinical studies	A study evaluating a medicine, conducted in humans
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
EMA	European Medicines Agency
FDA	The United States Food and Drug Administration
R&D	Abbreviation for research and development
IP	Intellectual properties, for example patents
Monoclonal antibody	A type of antibody produced by a single clone of cells
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42
Tolerability	The degree of side effects from a medicine that can be tolerated by a patient

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma Company specializing in the treatment of Alzheimer's disease, which focuses on targeting toxic amyloid-beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide™ technology makes it possible to develop disease-modifying treatments that accurately target the toxic amyloid-beta oligomers that are central to the onset and progression of the disease. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050. Based on the same technology, the Company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The Company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Pepparedsleden 1, SE-431 83,
Mölndal, Sweden

alzinova